World kidney day 2011: Protect your kidneys, save your heart

Brunei International Medical Journal

Volumn 7, Issue 1, 2011, Pages 1-7

  Couser, William G ^a   Riella, Miguel C ^a  

^a World Kidney Day 2011 Steering Committee ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857207758     PISSN: 15605876     EISSN: 20793146     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. World Health Organization. Preventing Chronic Diseases: A Vital Investment: WHO Global Report. 2005. 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes.
2. Anderson GF, Chu E. Expanding priorities - Confronting chronic disease in countries with low income. N Engl J Med. 2007;356: 209-11.
3. Narayan KM, Ali MK, Koplan JP. Global noncommunicable diseases-where worlds meet. N Engl J Med. 2010; 363:1196-8.
4. Ritz E, Bakris G; World Kidney Day Organising Committee. World Kidney Day: hypertension and chronic kidney disease. Lancet. 2009; 373:1157-8.
5. Atkins RC, Zimmet P, ISN-IFKF World Kidney Day Steering Committee. Diabetic kidney disease: Act now or pay later. Nat Rev Nephrol. 2010; 6:134-136.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296-305.
7. Tonelli M, Wiebe N, Culleton B, et al: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol. 2006; 17: 2034-47.
8. Hillege HL, Fidler V, Diercks GFH, et al; for the PREVEND study group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-82.
9. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110:32-5.
10. van Domburg RT, Hoeks SE, Welten GMJM, Chonchol M, Elhendy A, Poldermans D. Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Neph. 2008; 19:158-63.
11. Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol. 2008; 102:1668-7.
12. McCullough PA, Li S, Jurkovitz CT, et al; Kidney Early Evaluation Program Investigators. CKD and Cardiovascular Disease in Screened High-Risk Volunteer and General Populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008; 51, S38-S45.
13. McCullough PA, Jurkovitz CT, Pergola PE, et al; for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007; 167:1122-9.
14. McCullough PA, Li S, Jurkovitz CT, et al; KEEP Investigators. Chronic kidney disease: prevalence of premature cardiovascular disease and relationship to short-term mortality. AmHeart J. 2008; 156:277-83.
15. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008; 167:1226-33.
16. Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006; 69:1264-71.
17. Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ; CHARM Investigators Individuals at increased renal risk. J Amer Soc Nephrol. 2009; 20:852-62.
18. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M; Cholesterol and Recurrent Events (CARE) Trial Investigators. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006; 332:1426.
19. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J. Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol. 2009; 20:2617-24.
20. Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, et al. Prevalence of Chronic Kidney Disease in Elderly Patients with Normal Serum Creatinine Levels Undergoing Percutaneous Coronary Interventions. Gerontol. 2010; 56:51-4.
21. Hemmelgarn BR, Manns BJ, Lloyd A, et al; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010; 303:423-9.
22. Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Amer Soc Nephrol. 2009; 20:465-8.
23. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.
24. Abdelhafiz AH, Brown SH, Bello A, El Nahas M Chronic kidney disease in older people: physiology, pathology or both? Nephron Clin Pract. 2010; 116:19-24.
25. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular out- comes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345:861-9.
26. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359-64.
27. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352:1252-6.
28. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebocontrolled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-63.
29. The ESCAPE trial group: Strict blood pressure control and progression of renal failure in children. New Engl J Med. 2009; 361:1639-50.
30. Asselbergs FW, Diercks GF, Hillege HL, et al: Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809-16.
31. Atthobari J, Asselbergs FW, Boersma C, et al; PREVENT IT Study Group. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trail (PREVEND IT). Clin Ther. 2006; 28:432-44.
32. de Zeeuw D, Remuzzi G, Parving HH, et al: Albuminuria: a therapeutic target for cardiovascular protection in type 2 diabetic nephropathy. Circulation 2004; 110: 921-7.
33. Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in type II diabetic patients with nephropathy. Post hoc analysis from the Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007; 18:1540-6.
34. Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009; 20:893-900.
35. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008; 19:999-1007.
36. Fried L. Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol. 2009; 20:686-8.
37. El Nahas M. the global challenge of chronic kidney disease. (Nephrology Forum) Kidney Int. 2005; 68:2918-29.
38. Barsoum RS. Chronic Kidney disease in the developing world. New Engl J Med. 2006; 354:997-9.
39. Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W; Centers for Dis ease Control and Prevention Expert Panel. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009; 53:522-35.
40. James MT, Hemmelgarn, BR, Tonelli, M. Early recognition and prevention of CKD. Lancet 2010; 379:1296-309.
41. Perico N, Bravo RF, De Leon FR, Remuzzi G. Screening for chronic kidney disease in emerging countries: feasobility and hurdles. Nephrol Dial Transplant. 2009; 24:1355-8.